{"description":"Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution via expedited reporting (NCI AdEERs / CAeRs). All remaining CTCAEs collected by means other than expedited reporting are non-serious and are reported in the \"AE Other\" table. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":37,"description":"Patients with classic histology (WHO Grade II) supratentorial ependymoma who have undergone microscopic gross total resection (GTR1) or achieved CR either after first or second resection or after post-operative induction chemotherapy are assigned to observation. For patients without GTR1, induction chemotherapy is comprised of vincristine intravenously (IV) over 1 minute on days 1 and 8 of cycles 1 and 2, carboplatin IV over 15-60 minutes on day 1 of cycles 1 and 2, and cyclophosphamide IV over 30-60 minutes on days 1-2 of cycle 1 only. Patients also receive etoposide IV over 60-120 minutes on days 1-3 of cycle 2 only. Cycle 1 continues for 3 weeks and cycle 2 continues for 4 weeks in the absence of disease progression or unacceptable toxicity.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":37,"seriousNumAffected":0,"seriousNumAtRisk":37,"title":"Arm I: Observation"},{"deathsNumAffected":20,"deathsNumAtRisk":164,"description":"Patients with supratentorial ependymoma (Grade II without GTR1 or Grade III) or any infratentorial ependymoma who have undergone gross or near total resection (GTR or NTR) or achieved CR either after first or second resection or after post-operative induction chemotherapy are randomized to undergo conformal radiotherapy over 6-7 weeks followed by maintenance chemotherapy. Maintenance chemotherapy comprised of vincristine IV on days 1, 8, and 15 of cycles 1-3 only, etoposide IV over 60-120 minutes on days 1-3, cisplatin IV over 1-8 hours on day 1, and cyclophosphamide IV over 30-60 minutes on days 2-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without GTR or NTR at enrollment require induction chemotherapy (see Arm I) and possibly second surgery before randomization.","id":"EG001","otherNumAffected":22,"otherNumAtRisk":164,"seriousNumAffected":5,"seriousNumAtRisk":164,"title":"Arm II: Randomized to Radiation With Maintenance Chemotherapy"},{"deathsNumAffected":27,"deathsNumAtRisk":161,"description":"Patients with supratentorial ependymoma (Grade II without GTR1 or ST Grade III) or any infratentorial ependymoma (Grade II or III) who have undergone gross or near total resection or achieved CR either after first or second resection or after post-operative induction chemotherapy are randomized to undergo conformal radiotherapy over 6-7 weeks and then undergo observation.","id":"EG002","otherNumAffected":10,"otherNumAtRisk":161,"seriousNumAffected":0,"seriousNumAtRisk":161,"title":"Arm III: Randomized to Radiation Only"},{"deathsNumAffected":22,"deathsNumAtRisk":63,"description":"Patients with subtotal resection after induction chemotherapy (see Arm I) and second surgery are nonrandomly assigned to Arm II treatment.","id":"EG003","otherNumAffected":15,"otherNumAtRisk":63,"seriousNumAffected":1,"seriousNumAtRisk":63,"title":"Arm IV: Nonrandomly Assigned to Arm II Treatment"},{"deathsNumAffected":4,"deathsNumAtRisk":24,"description":"Patients with tumor other than ependymoma or withdrew before protocol-specified radiotherapy administered","id":"EG004","otherNumAffected":4,"otherNumAtRisk":24,"seriousNumAffected":0,"seriousNumAtRisk":24,"title":"Not Ependymoma or Withdrew Before Radiation"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":1,"numAtRisk":24}],"term":"Anemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":1,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":1,"numAtRisk":24}],"term":"Febrile neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Ear and labyrinth disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":1,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Ear and labyrinth disorders - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Ear and labyrinth disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":1,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Hearing impaired"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":1,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Fever"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":1,"numAtRisk":24}],"term":"Meningitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":2,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":1,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Sepsis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":4,"numAtRisk":164},{"groupId":"EG002","numAffected":2,"numAtRisk":161},{"groupId":"EG003","numAffected":2,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Lymphocyte count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":6,"numAtRisk":164},{"groupId":"EG002","numAffected":2,"numAtRisk":161},{"groupId":"EG003","numAffected":3,"numAtRisk":63},{"groupId":"EG004","numAffected":1,"numAtRisk":24}],"term":"Neutrophil count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":3,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":3,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Platelet count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":4,"numAtRisk":164},{"groupId":"EG002","numAffected":2,"numAtRisk":161},{"groupId":"EG003","numAffected":4,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"White blood cell decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":1,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Hyperglycemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":1,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Hypocalcemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":1,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Hypoglycemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":4,"numAtRisk":164},{"groupId":"EG002","numAffected":1,"numAtRisk":161},{"groupId":"EG003","numAffected":2,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Hypokalemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":1,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":2,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Hypomagnesemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":1,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Hyponatremia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":1,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Hypophosphatemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":1,"numAtRisk":164},{"groupId":"EG002","numAffected":2,"numAtRisk":161},{"groupId":"EG003","numAffected":3,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":3,"numAtRisk":164},{"groupId":"EG002","numAffected":3,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Central nervous system necrosis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":2,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Edema cerebral"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":1,"numAtRisk":161},{"groupId":"EG003","numAffected":2,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Hydrocephalus"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":1,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Peripheral motor neuropathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":1,"numAtRisk":24}],"term":"Vagus nerve disorder"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":1,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Delirium"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":1,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Hallucinations"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":1,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Hypoxia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":2,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Respiratory failure"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":1,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Respiratory, thoracic and mediastinal disorders - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":1,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Stridor"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":2,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Death NOS"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":2,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Sepsis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":1,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":0,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Hypernatremia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":37},{"groupId":"EG001","numAffected":0,"numAtRisk":164},{"groupId":"EG002","numAffected":0,"numAtRisk":161},{"groupId":"EG003","numAffected":1,"numAtRisk":63},{"groupId":"EG004","numAffected":0,"numAtRisk":24}],"term":"Treatment related secondary malignancy"}],"timeFrame":"Enrollment up to 10 years after enrollment."}